Page 86 - Mesenchymal Stem cells, Exosomes and vitamins in the fight aginst COVID

Intravascular Mesenchymal Stem Cells to Treat Organ Failure and Possible Application in COVID-19

Improvement in MI episodes and QOL in patients with Improvement in end-systolic strain in the segments with a transmural infarct along with peak-systolic strain rate along No change in LVEF or improvement in exercise time or peak oxygen consumption (2–3 Reduction in death, MI, need for revascularization, recurrence of MI, and/or rehospitalization for health failure. Increase in left ventricular contractility of Improvement in NYHA score

Findings angina. with systolic BP. weeks to 3 years). infarcted segments.

Follow- Up 6 4 36 24 6 12 6 36

LVEF Impact Yes - improvement Not assessed No Not assessed Yes Yes - improvement No No

Outcome Yes Yes No Yes Yes Yes Yes No

Condition IHD IHD IHD IHD IHD IHD IHD IHD

Delivery Method IC IC IC IC IC IC IC IC

Type of Stem Cell BM MSC + BM MNC BM MNC BM MNC BM MNC BM MSC BM MNC BM MNC BM MNC

Number of SCs 7.5 million MSC [Pas 1–2] and MNC each 304 million 68 million Not disclosed 12–13 million [Pas 0] 248 million 100 million 68 million

Table 2 con't. MSC therapy studies treating cardiac failure.
BMA (mL) 30–50 Not disclosed 50 Not disclosed 20–40 100 80–100 50

No. of Patients in Treatment Group 10 33 50 100 16 19 30 50

Type of Study Case series RCT RCT RCT RCT RCT RCT RCT

Year 2009 2009 2009 2009 2010 2010 2010 2010

Author Lasala et al (72) Herbots et al, Eur Heart J 2009; 30:662-670 Beitnes et al, Heart 2009; 95:1983-1989 Assmus et al, Circulation: Heart Failure 2010; 3:89-96 Yang et al, Cardiovascular therapeutics 2010; 28:380-385 Piepoli et al, European Journal of Heart Failure 2010; 12:172-180 Traverse et al, Am Heart J 2010; 160:428-434 Beitnes et al, Eur J Echocardiogr 2011; 12:98-106

www.painphysicianjournal.com S403